Evidence map›Paper›PMID 31234796›Full record

ArticleBMC microbiology2019

Stationary phase persister formation in Escherichia coli can be suppressed by piperacillin and PBP3 inhibition.

Sandra J Aedo, Mehmet A Orman, Mark P Brynildsen

Open access · goldAbstract read
In one paragraph

Article in BMC microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Metabolites Potentiate Nitrofurans in Nongrowing Escherichia coli.Antimicrobial agents and chemotherapy · 2021
    Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sandra J AedoDepartment of Chemical and Biological Engineering, Princeton University, Hoyt Laboratory, 25 William Street, Princeton, NJ, 08544, USA.
Mehmet A OrmanDepartment of Chemical and Biological Engineering, Princeton University, Hoyt Laboratory, 25 William Street, Princeton, NJ, 08544, USA.
Mark P BrynildsenDepartment of Chemical and Biological Engineering, Princeton University, Hoyt Laboratory, 25 William Street, Princeton, NJ, 08544, USA. mbrynild@princeton.edu.ORCID 0000-0001-5707-8894
Princeton University · US

Funding

Exploring Persister Antibiotic Responses as a Source of Biomarkers and Elimination StrategiesR21AI115075 · NIAID · PRINCETON UNIVERSITY · PI BRYNILDSEN, MARK P · 2015 to 2016
$446k
High-throughput Quantification of Persister Physiology at the Systems LevelR21AI117009 · NIAID · PRINCETON UNIVERSITY · PI BRYNILDSEN, MARK P · 2016 to 2017
$430k
NIAID NIH HHS R21 AI115075NIAID NIH HHS R21 AI117009
6 · The paper itself

Abstract

backgroundPersisters are rare phenotypic variants within a bacterial population that are capable of tolerating lethal antibiotic concentrations. Passage through stationary phase is associated with the formation of persisters (type I), and a major physiological response of Escherichia coli during stationary phase is cell wall restructuring. Given the concurrence of these processes, we sought to assess whether perturbation to cell wall synthesis during stationary phase impacts type I persister formation.

resultsWe tested a panel of cell wall inhibitors and found that piperacillin, which primarily targets penicillin binding protein 3 (PBP3 encoded by ftsI), resulted in a significant reduction in both β-lactam (ampicillin, carbenicillin) and fluoroquinolone (ofloxacin, ciprofloxacin) persister levels. Further analyses showed that piperacillin exposure through stationary phase resulted in cells with more ATP, DNA, RNA, and protein (including PBPs) than untreated controls; and that their physiology led to more rapid resumption of DNA gyrase supercoiling activity, translation, and cell division upon introduction into fresh media. Previously, PBP3 inhibition had been linked to antibiotic efficacy through the DpiBA two component system; however, piperacillin suppressed persister formation in ΔdpiA to the same extent as it did in wild-type, suggesting that DpiBA is not required for the phenomenon reported here. To test the generality of PBP3 inhibition on persister formation, we expressed FtsI Ser307Ala to genetically inhibit PBP3, and suppression of persister formation was also observed, although not to the same magnitude as that seen for piperacillin treatment.

conclusionsFrom these data we conclude that stationary phase PBP3 activity is important to type I persister formation in E. coli.

Indexed as

beta-LactamsCell WallDrug Resistance, BacterialEscherichia coliEscherichia coli ProteinsFluoroquinolonesMutationPenicillin-Binding ProteinsPeptidoglycan GlycosyltransferasePhenotypePiperacillinProtein KinasesTranscription Factorsbeta-LactamsCitA protein, E coliCitB protein, E coliEscherichia coli ProteinsFluoroquinolonesFtsI protein, E coliPenicillin-Binding ProteinsPeptidoglycan GlycosyltransferasePiperacillinProtein KinasesTranscription FactorsE. coliFluoroquinolonePBP3PersistersPiperacillinβ-Lactam

Identifiers

PMID31234796
PMCPMC6591824
OpenAlexW2953384242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.